Tivic Health shares rise 10.76% premarket after filing two new patents for cancer therapies and vagus nerve stimulation device.

Tivic Health (TIVC) jumped 10.76% in premarket trading after announcing the filing of two new patent applications with the U.S. Patent and Trademark Office. The first patent explores TLR5 agonists like Entolimod as adjunctive therapies for advanced-stage cancer, while the second focuses on non-invasive vagus nerve stimulation systems. These filings expand the company’s intellectual property portfolio and open potential partnership opportunities, as highlighted by CEO Jennifer Ernst. The move follows recent strategic shifts toward biopharmaceuticals and ongoing FDA engagement for Entolimod’s regulatory pathway, despite a reported Q2 revenue decline. The stock’s sharp premarket gain aligns with investor optimism over expanded IP and therapeutic applications, underscoring renewed focus on high-impact cancer and immune therapies.